Day: September 19, 2018

  1. Home
  2. Archives: September 2018

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis  

Recent Posts

  • Prilenia enrolls first ALS patient in their Phase II / III study
  • Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
  • Prilenia shows positive effect on functional capacity in Huntigton’s Disease
  • Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
  • Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board